

## **Nevada Medicaid**

Submit fax request to: 855-455-3303

Please note: All information below is required to process this request.

## Qutenza® (capsaicin) Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED.

Member Information (required)			Provider Information (required)			
Member Name:			Provider Name:			
Insurance ID#:			NPI#:		Specialty:	
Date of Birth:			Office Phone:			
Street Address:			Office Fax:			
City:	State:	Zip:	Office Street Address:			
Phone:		- 1	City:	S	tate:	Zip:
Medication Information (required)						
Medication Name:			Strength:		Dosage Form:	
☐ Check if requesting brand ☐ Check if request is for initial trial ☐ Check if request is for recertification of therapy			Directions for Use:			
Clinical Information (required)						
Select the diagnosis below:						
☐ Diagnosis of neuropathic pain associated with postherpetic neuralgia.						
□ Diagnosis of neuropathic pain associated with diabetic peripheral neuropathy of the feet.						
☐ Other diagnosis: ICD-10 Code(s):						
Drug-Specific Information (required)						
☐ The recipient has a history of failure or intolerance to over-the-counter capsaicin.						
For recertification:  At least three months have transpired since the last Qutenza®application/administration.  The recipient experienced pain relief with a prior course of Qutenza®.  The recipient is experiencing a return of neuropathic pain.						

Attach any additional comments, diagnoses, symptoms, medications tried or failed, or other information the physician feels is important to this review.

Please note: This request may be denied unless all required information is received. For urgent or expedited requests please call 1-800-711-4555. This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

FA-192 06/06/2022 Page 1 of 1